The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Open accessAbstract
The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic “readers” and play a key role in the regulation of gene transcription. BET proteins are considered to be attractive therapeutic targets for cancer and other human diseases. Recently, heterobifunctional small-molecule BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation. Herein, we present our design, synthesis, and evaluation of a new class of PROTAC BET degraders. One of the most promising compounds, 23, effectively degrades BRD4 protein at concentrations as low as 30 pM in the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors. These data establish that compound 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D. C., Rezai, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 420
Small-Molecule Inhibition of BRDT for Male Contraception
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.045 · Cited by 416
Targeting Epigenetic Readers in Cancer
Dawson, M. A., Kouzarides, T., & Huntly, B. J. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112635 · Cited by 397
Stathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.-P., de La Motte Rouge, T., Uro-Coste, E., de Braud, F., Pelosi, G., & French, C. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1335 · Cited by 378
Readout of Epigenetic Modifications
Patel, D. J., & Wang, Z. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-072711-165700 · Cited by 313
Mirguet, O., Gosmini, R., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 305
Boi, M., Gaudio, E., Bonetti, P., Kwee, I., Bernasconi, E., Tarantelli, C., Rinaldi, A., Testoni, M., Cascione, L., Ponzoni, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1561 · Cited by 284
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
Coudé, M.-M., Braun, T., Berrou, J., Dupont, M., Bertrand, S., Masse, A., Raffoux, E., Itzykson, R., Delord, M., Riveiro, M. E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4131 · Cited by 274
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1
Banerjee, C., Archin, N., Michaels, D., Belkina, A. C., Denis, G. V., Bradner, J., Sebastiani, P., Margolis, D. M., & Montano, M. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0312165 · Cited by 256
Reactivation of Latent HIV-1 by Inhibition of BRD4
Zhu, J., Gaiha, G. D., John, S. P., Pertel, T., Chin, C. R., Gao, G., Qu, H., Walker, B. D., Elledge, S. J., & Brass, A. L. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.008 · Cited by 244
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Chaidos, A., Caputo, V., Gouvedenou, K., Liu, B., Marigo, I., Chaudhry, M. S., Rotolo, A., Tough, D. F., Smithers, N. N., Bassil, A. K., et al. (2014) · Blood · doi:10.1182/blood-2013-01-478420 · Cited by 203
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199
Self-citationStructure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
Xu, R., Zhao, Y., Liu, L., Bai, L., Yang, C., Zhou, B. N., Meagher, J. L., Chinnaswamy, K., Stuckey, J. A., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00613 · Cited by 113
Self-citationOdore, E., Lokiec, F. M., Cvitkovic, E., Békradda, M., Herait, P., Bourdel, F., Kahatt, C. M., Raffoux, E., Stathis, A., Thiéblemont, C., et al. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0327-6 · Cited by 97
A review of the history, properties, and use of the immunomodulatory compound lenalidomide
Zeldis, J. B., Knight, R., Hussein, M. A., Chopra, R., & Muller, G. W. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05974.x · Cited by 80
Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation.
Denis, G. V. (2010) · PubMed · Cited by 65
Small Molecule Bromodomain Inhibitors
Chung, C. (2012) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-396493-9.00001-7 · Cited by 50
Cited by
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 800
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Li, X., & Song, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00885-3 · Cited by 521
Metadata
- Authors
- Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.-Y., Zhao, Y., McEachern, D., Przybranowski, S., Wen, B., Sun, D., & Wang, S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-03-24
- Volume
- 61
- Issue
- 2
- Pages
- 462-481
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2604040637
- Cited by
- 358
- References
- 31
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.